A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients

Patients who had an ASCVD event at an Intermountain hospital will be screened for eligibility to be randomized. Subjects who meet eligibility criteria will be randomized 1:1 to receive targeted care of their LDL-C through a pharmacist-driven management program or not. Patients may opt-out of receiving LDL-C management by the pharmacy team at any time. The purpose of this program is to increase the proportion of patients who achieve guideline-based recommendations of LDL-C levels of \<70 mg/dL by increasing statin and/or LLT adherence and LDL-C testing. Data collection as part of the study will continue until the last person randomized has had 1-year of follow-up.

NCT Number	NCT06571162
Lead Sponsor	Intermountain Health Care, Inc.
Conditions	Atherosclerotic Cardiovascular Disease
Enrollment	400 participants
Start Date	2025-01-30
Primary Completion	2028-01 (estimated)
Study Completion	2028-09 (estimated)
Updated on ClinicalTrials.gov	2025-05-06